CAM
TRIB

ClariVest Asset Management’s Trinity Biotech TRIB Stock Holding History

ClariVest Asset Management’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-51
Closed -$3K – 656
2015
Q3 		$3K Hold
51
– – ﹤0.01% 520
2015
Q2 		$5K Hold
51
– – ﹤0.01% 501
2015
Q1 		$5K Hold
51
– – ﹤0.01% 506
2014
Q4 		$4K Hold
51
– – ﹤0.01% 470
2014
Q3 		$5K Hold
51
– – ﹤0.01% 490
2014
Q2 		$6K Hold
51
– – ﹤0.01% 486
2014
Q1 		$6K Buy
+51
New +$6.69K ﹤0.01% 504
2013
Q4 		– Sell
-77
Closed -$8K – 652
2013
Q3 		$8K Hold
77
– – ﹤0.01% 479
2013
Q2 		$7K Buy
+77
New +$6.39K ﹤0.01% 458

Other funds holding TRIB

Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
AAM
ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

ClariVest Asset Management's TRIB Position: Q4 2015 in Review

ClariVest Asset Management sold out of Trinity Biotech (TRIB) in Q4 2015, closing a stake of 51 shares — an estimated $3K sold.

ClariVest Asset Management first reported a position in TRIB in Q2 2013 and held it in 9 quarters. The position peaked at $8K in Q3 2013. 82 funds tracked by Wall St. Rank hold TRIB as of Q4 2015.

  • ClariVest Asset Management reported no remaining Trinity Biotech position as of Q4 2015 after selling out during the quarter.
  • ClariVest Asset Management sold 51 Trinity Biotech shares in Q4 2015, an estimated $3K.
  • ClariVest Asset Management first reported a position in Trinity Biotech in Q2 2013 and held it in 9 quarters.
  • ClariVest Asset Management's Trinity Biotech position peaked at $8K in Q3 2013.
  • 82 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2015.

Based on ClariVest Asset Management's 13F filing for Q4 2015, filed 27 Jan 2016.